ProQR Therapeutics NV宣布,其候选药物Ax-0810在一期临床试验中获得了积极的靶点结合数据,这标志着公司Axiomer RNA编辑平台首次获得了临床验证。
ProQR Therapeutics NV宣布,其候选药物Ax-0810在一期临床试验中获得了积极的靶点结合数据,这标志着公司Axiomer RNA编辑平台首次获得了临床验证。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.